German billionaire Dietmar Hopp, the founder of SAP business softwares, has invested about 200 million euros in the last two years, and plans to invest 50 million more.
“The biotechnology wave is similar to the information technology wave of the 1980s and 1990s,” Hopp said during an interview Monday, explaining why he has invested €200 million, or $253 million, in biotechnology companies over the past four years.
Among the 14 companies Hopp has invested on are mainly Germany-based biopharmaceutical firms, focusing on cancer and diseases of the central nervous system. Among them are:
Lion Bioscience/Axaron Bioscience